.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Colorcon
Fuji
Federal Trade Commission
Chinese Patent Office
Express Scripts
Argus Health
Healthtrust
Moodys
Accenture

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021835

« Back to Dashboard
NDA 021835 describes CLOBEX, which is a drug marketed by Galderma Labs Lp and Galderma Labs and is included in three NDAs. It is available from five suppliers. There are seven patents protecting this drug and three Paragraph IV challenges. Additional details are available on the CLOBEX profile page.

The generic ingredient in CLOBEX is clobetasol propionate. There are thirteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

Summary for NDA: 021835

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Formulation / Manufacturing:see details

Pharmacology for NDA: 021835

Suppliers and Packaging for NDA: 021835

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLOBEX
clobetasol propionate
SPRAY;TOPICAL 021835 NDA Galderma Laboratories, L.P. 0299-3849 0299-3849-01 1 BOTTLE in 1 CARTON (0299-3849-01) > 10 mL in 1 BOTTLE
CLOBEX
clobetasol propionate
SPRAY;TOPICAL 021835 NDA Galderma Laboratories, L.P. 0299-3849 0299-3849-02 1 BOTTLE in 1 CARTON (0299-3849-02) > 59 mL in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY;TOPICALStrength0.05%
Approval Date:Oct 27, 2005TE:ATRLD:Yes
Patent:► SubscribePatent Expiration:Feb 12, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 24, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Merck
Colorcon
Medtronic
AstraZeneca
Baxter
Cerilliant
Dow
Argus Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot